10x Genomics, Inc. TXG EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from 10x Genomics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s EBITDA margin?
- 10x Genomics, Inc. (TXG) reported EBITDA margin of -0.1% in Q1 2026.
- How has 10x Genomics, Inc.'s EBITDA margin changed year-over-year?
- 10x Genomics, Inc.'s EBITDA margin increased by 99.6% year-over-year, from -22% to -0.1%.
- What is the long-term trend for 10x Genomics, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s EBITDA margin has grown at a -53.3% compound annual growth rate (CAGR), from -174% to -3.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.